Published: 6 September 2018
Publications
Recent Approvals of Medicines Containing a New Active Ingredient
Prescriber Update 39(3): 41
September 2018
For the period 16 April 2018 to 15 July 2018.
| Trade name (active ingredient) | Dose form and strength | Therapeutic area |
|---|---|---|
| Acarizax (Dermatophagoides farinae allergen extract; D. pteronyssinus allergen extract) | Sublingual tablet 12 SQ-HDM | House dust mite allergy |
| Afstyla (lonoctocog alpha) | Injection with diluent 250, 500, 1000, 1500 2000, 2500 and 3000 IU | Haemophilia A (congenital FVIII deficiency) |
| Cystadane (betaine) | Powder for oral solution 180 g | Homocystinuria |
| Lonquex (lipegfilgastim) | Solution for injection 6 mg/0.6 mL | Neutropenia associated with cytotoxic chemotherapy |
| Maviret (glecaprevir, pibrentasvir) | Film coated tablet 100 mg/40 mg | Chronic hepatitis C infection |
See the Medsafe website for data sheets of currently marketed medicines
(www.medsafe.govt.nz/Medicines/infoSearch.asp).
